Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2022-08-01 00:00:00 ET · period of report 2022-07-28 · accession 0001209191-22-043769 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-08-01 | 2022-07-28 | ORMP | Kidron Miriam | CSO, Dir | A - Grant | — | +118.0K | 217.7K | +118% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-28 | A | A | 84,000 | — | 301,666 | D | — | — | (F2) Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 28,000 shall vest on each of January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. |
| 2 | Common | Common Stock | 2022-07-28 | A | A | 34,000 | — | 217,666 | D | — | — | (F1) Represents Common Stock granted by the Issuer that vested on August 1, 2022. |